Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Once Daily PMR (Cilostazol ER) vs Twice Daily Cilostazol IR
NCT06167265Phase 1Completed
- Sponsor
- Genovate Biotechnology
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cilostazol in intermittent claudication (IC) (2 arms), sponsored by Genovate Biotechnology. Primary endpoints: Area under the curve, from time zero to last measureable time point and AUC from time zero to infinity. Started Nov 2023; status: completed.
02
Drugs
cilostazol
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT06167265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167265.